AWH Stock Overview
Aspira Women’s Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States.
Aspira Women's Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.95|
|52 Week High||US$3.92|
|52 Week Low||US$0.32|
|1 Month Change||2.99%|
|3 Month Change||72.70%|
|1 Year Change||-74.26%|
|3 Year Change||72.73%|
|5 Year Change||-24.00%|
|Change since IPO||-99.70%|
Recent News & Updates
Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M
Aspira Women’s Health press release (NASDAQ:AWH): Q2 GAAP EPS of -$0.07 in-line. Revenue of $2.06M (+14.4% Y/Y) misses by $0.34M.
Is Aspira Women's Health (NASDAQ:AWH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
|AWH||US Medical Equipment||US Market|
Return vs Industry: AWH underperformed the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: AWH underperformed the US Market which returned -8.9% over the past year.
|AWH Average Weekly Movement||21.2%|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: AWH is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: AWH's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Aspira Women’s Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.
Aspira Women's Health Fundamentals Summary
|AWH fundamental statistics|
Is AWH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AWH income statement (TTM)|
|Cost of Revenue||US$3.79m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||-483.93%|
How did AWH perform over the long term?See historical performance and comparison
Is AWH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AWH?
Other financial metrics that can be useful for relative valuation.
|What is AWH's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AWH's PS Ratio compare to its peers?
|AWH PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
KRMD KORU Medical Systems
AWH Aspira Women's Health
Price-To-Sales vs Peers: AWH is expensive based on its Price-To-Sales Ratio (14.3x) compared to the peer average (8.5x).
Price to Earnings Ratio vs Industry
How does AWH's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: AWH is expensive based on its Price-To-Sales Ratio (14.3x) compared to the US Medical Equipment industry average (4.5x)
Price to Sales Ratio vs Fair Ratio
What is AWH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||14.3x|
|Fair PS Ratio||6.9x|
Price-To-Sales vs Fair Ratio: AWH is expensive based on its Price-To-Sales Ratio (14.3x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).
Share Price vs Fair Value
What is the Fair Price of AWH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AWH ($0.95) is trading below our estimate of fair value ($4.24)
Significantly Below Fair Value: AWH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Aspira Women's Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AWH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AWH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AWH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AWH's revenue (41.7% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: AWH's revenue (41.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AWH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Aspira Women's Health performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AWH is currently unprofitable.
Growing Profit Margin: AWH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AWH is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.
Accelerating Growth: Unable to compare AWH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: AWH has a negative Return on Equity (-256.19%), as it is currently unprofitable.
Discover strong past performing companies
How is Aspira Women's Health's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AWH's short term assets ($23.0M) exceed its short term liabilities ($7.0M).
Long Term Liabilities: AWH's short term assets ($23.0M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: AWH has more cash than its total debt.
Reducing Debt: AWH's debt to equity ratio has reduced from 37.1% to 21.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AWH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AWH has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.1% each year.
Discover healthy companies
What is Aspira Women's Health current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AWH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AWH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AWH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AWH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AWH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nicole Sandford (52 yo)
Ms. Nicole Sandford, C.P.A., serves as President, Chief Executive Officer since March 1, 2022 and served as its Director at Aspira Women's Health Inc. since March 1, 2022 until July 2022. She had been Inde...
Experienced Management: AWH's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: AWH's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aspira Women's Health Inc.'s employee growth, exchange listings and data sources
- Name: Aspira Women's Health Inc.
- Ticker: AWH
- Exchange: NasdaqCM
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$106.682m
- Shares outstanding: 112.30m
- Website: https://aspirawh.com
Number of Employees
- Aspira Women's Health Inc.
- Building III
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.